{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:43:27Z","timestamp":1747183407382,"version":"3.40.5"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>GSK3358699 is a mononuclear myeloid\u2010targeted bromodomain and extra\u2010terminal domain (BET) family inhibitor which demonstrates immunomodulatory effects in vitro. This phase 1, randomized, first\u2010in\u2010human study evaluated the safety, pharmacokinetics, and pharmacodynamics of GSK3358699 in healthy male participants (NCT03426995).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Part A (N\u00a0=\u200923) included three dose\u2010escalating periods of 1\u201040\u2009mg of GSK3358699 or placebo in two cohorts in a single ascending\u2010dose crossover design. Part C (N\u2009=\u200925) was planned as an initial dose of 10\u00a0mg of GSK3358699 or placebo daily for 14\u2009days followed by selected doses in four sequential cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In part A, exposure to GSK3358699 and its metabolite GSK3206944 generally increased with increasing doses. The median initial half\u2010life ranged from 0.7 to 1.1 (GSK3358699) and 2.1 to 2.9 (GSK3206944) hours after a single dose of 1\u201040\u2009mg. GSK3206944 concentrations in monocytes were quantifiable at 1\u2010hour post\u2010dose following 10\u00a0mg of GSK3358699 and 1 and 4\u00a0hours post\u2010dose following 20\u201040\u2009mg. Mean predicted percentage inhibition of ex vivo lipopolysaccharide\u2010induced monocyte chemoattractant protein (MCP)\u20101 reached 75% with 40\u2009mg of GSK3358699. GSK3358699 did not inhibit interleukin (IL)\u20106 and tumour necrosis factor (TNF).<\/jats:p><jats:p>The most common adverse event (AE) was headache. Four AEs of nonsustained ventricular tachycardia were observed across parts A and C. One serious AE of atrial fibrillation (part C) required hospitalization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Single doses of GSK3358699 are generally well tolerated with significant metabolite concentrations detected in target cells. A complete assessment of pharmacodynamics was limited by assay variability. A causal relationship could not be excluded for cardiac\u2010related AEs, resulting in an inability to identify a suitable repeat\u2010dose regimen and study termination.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15137","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:11:38Z","timestamp":1636848698000},"page":"2140-2155","source":"Crossref","is-referenced-by-count":4,"title":["A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid\u2010targeted bromodomain and extra\u2010terminal domain inhibitor"],"prefix":"10.1111","volume":"88","author":[{"given":"Jack A.","family":"Brown","sequence":"first","affiliation":[{"name":"GlaxoSmithKline R&amp;D  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7693-078X","authenticated-orcid":false,"given":"Joanne","family":"Bal","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Stevenage  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Simeoni","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, GSK House  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Williams","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, GSK House  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palwinder K.","family":"Mander","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Stevenage  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Soden","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Stevenage  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Daga","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Uxbridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Fahy","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, GSK House  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel K.","family":"Wong","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Stevenage  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie C.","family":"Bloomer","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D  Ware Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Erwig","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Stevenage  Stevenage UK"},{"name":"Johnson &amp; Johnson  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Cui","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, GSK House  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Disala","family":"Fernando","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Clinical Unit Addenbrooke's Hospital  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Carnaghan","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Clinical Unit Addenbrooke's Hospital  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Banham\u2010Hall","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Clinical Unit Addenbrooke's Hospital  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hopkins","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Clinical Unit Addenbrooke's Hospital  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill G.","family":"Davis","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Clinical Unit Addenbrooke's Hospital  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao J. D.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Clinical Unit Addenbrooke's Hospital  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabinder K.","family":"Prinjha","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&amp;D Stevenage  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21730"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00384-4"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0022034514534261"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.06.001"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1615601114"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130376"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.621093"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.183640"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444862"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202838"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201500272"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01743"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071527"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.315929"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.08.001"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T22:30:28Z","timestamp":1693002628000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/bcp.15137"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15137","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2021,12,18]]}}}